SUSPECT ADVERSE REACTION REPORT

NI-Tolmar-TLM-2025-04570

I. REACTION INFORMATION

1. PATIENT INITIALS (first, last)	1a. COUNTRY	2. DATE OF BIRTH			2a. AGE Years	3. SEX	4-6 REACTION ONSET			8-12 CHECK ALL APPROPRIATE TO ADVERSE REACTION
		Day	Month	Year			Day	Month	Year	
AACS	NICARAGUA	15	Sep	2014	10	Female	21	Feb	2024	

7+13 DESCRIBE REACTION(S) (including relevant tests/lab data)

1) Off-label use (Off label use (10053762), Off label use (10053762))
(21/Feb/2024 -) - Unknown
2) Cessation of therapy (Therapy cessation (10065154), Therapy cessation (10065154))
(19/May/2025 -) - Unknown

- ☐ PATIENT DIED
- ☐ LIFE THREATENING
- ☐ INVOLVED OR PROLONGED INPATIENT HOSPITALIZATION
- ☐ RESULTS IN PERSISTENCE OR SIGNIFICANT DISABILITY/INCAPACITY
- ☐ CONGENITAL ANOMALY
- ☐ OTHER MEDICALLY IMPORTANT CONDITION

II. SUSPECT DRUG(S)INFORMATION

14. SUSPECT DRUG(S)(include generic name)

1) Eligard® (Leuprolide acetate, Leuprolide acetate) (Suspect) (22.5 Milligram, Injection)(Unknown)

Cont..

20. DID EVENT ABATE AFTER STOPPING DRUG? ☐ YES ☐ NO ☑ NA

15. DAILY DOSE(S)

1) (22.5 milligram(s), 1 in 3 Month)

16. ROUTE(S) OF ADMINISTRATION

1) Subcutaneous

21. DID EVENT REAPPEAR AFTER REINTRODUCTION ☐ YES ☐ NO ☑ NA

(NA : Not Applicable)

17. INDICATION(S) FOR USE

1) Precocious puberty [10058084 - Precocious puberty]

18. THERAPY DATE(S) (from/to)	19. THERAPY DURATION
1) (21/Feb/2024 - 19/May/2025)	1) 454 Days

III. CONCOMITANT DRUG(S) AND HISTORY

22. CONCOMITANT DRUG(S) AND DATES OF ADMINISTRATION (exclude those used to treat reaction)

No concomitants used/reported

23. OTHER RELEVANT HISTORY (e.g. diagnostics, allergies, pregnancy with last month of period, etc.)

1) PRECOCIOUS PUBERTY (10058084, Precocious puberty) (Continuing: Yes)

IV. MANUFACTURER INFORMATION

24a. NAME AND ADDRESS OF MANUFACTURER

Name : Tolmar, Inc
701 Centre Avenue
Fort Collins, CO, 80526, UNITED STATES OF AMERICA

Study Information
Study Name: NA
EudraCT Number:
Protocol No.: NA
Center No.:
Subject Id :

24.REPORT NULLIFIED	24b. MFR CONTROL NO.
☐ YES ☐ NO	NI-Tolmar-TLM-2025-04570
24c. DATE RECEIVED BY MANUFACTURER	24d. REPORT SOURCE
09/Jul/2025	☑ STUDY ☐ LITERATURE ☐ HEALTH PROFESSIONAL
DATE OF THIS REPORT	25a. REPORT TYPE
19/Jul/2025	☑ INITIAL ☐ FOLLOWUP

= Continuation attached sheet(s)..

Continuation Sheet for CIOMS report

7+13 DESCRIBE REACTION(S) (including relevant tests/lab data) (Continuation...)

Event Description :

This study report from Nicaragua was received by Adium via Patient Support Program "ASOFARMA A TU LADO" (Reference number: NI-ADIUM-NI-0055-20250709) on 09-Jul-2025 from a consumer (non-healthcare professional) regarding a child, 10-year-old female patient who experienced non-serious events of "Off-label use " (Off label use) and "Cessation of therapy" (Therapy cessation) during Eligard (leuprolide acetate) 22.5 mg therapy for precocious puberty. The needle component of the constituent device was not identified in the report. The report was sent to Tolmar on 10-Jul-2025.

The patient's medical history was unknown and current condition included precocious puberty.

Concomitant medications were unknown.

On 21-Feb-2024, the patient began to receive Eligard (leuprolide acetate) 22.5 mg every 3 months via subcutaneous route for precocious puberty (Lot numbers and Expiration dates were not provided).

On 19-May-2025, the patient's treatment was stopped. No further details were provided.

Corrective treatment was not reported.

Action taken with Eligard in response to the events off label use and therapy cessation was drug withdrawn. De-challenge and re-challenge were not applicable.

The outcome of the events off label use and therapy cessation was unknown.

The reporter did not assess the seriousness of the events off label use and therapy cessation.

The reporter provided the causality of the event off label use as related in relationship to Eligard and Eligard unspecified device.

The reporter did not provide the causality of the event therapy cessation in relationship to Eligard and Eligard unspecified device.

No further information is expected as consent to be contacted was not provided.

Listedness

Off label use>Eligard>Unlisted as per CCDS>07-Nov-2024
Off label use>Eligard>Unlisted as per USPI>Feb-2025
Off label use>Eligard unspecified device>Unlisted as per USPI>Feb-2025
Off label use>Eligard>Unlisted as per Canadian monograph>02-Apr-2025

Therapy cessation>Eligard>Unlisted as per CCDS>07-Nov-2024
Therapy cessation>Eligard>Unlisted as per USPI>Feb-2025
Therapy cessation>Eligard unspecified device>Unlisted as per USPI>Feb-2025
Therapy cessation>Eligard>Unlisted as per Canadian monograph>02-Apr-2025

Company Remarks (Sender's Comments) :

Evaluator comment (Tolmar): This is regarding a child 10-year-old female patient who had "Off-label use " (Off label use) and Therapy cessation ("Cessation of therapy") during Eligard (leuprolide acetate) 22.5 mg therapy for precocious puberty. Tolmar assessed the event as non-serious since it does not meet the ICH seriousness criteria and is not an IME event. The reported events off-label use and Therapy cessation were assessed as not related to Eligard (drug and device) as the event occurred with the product due to human action, rather due to the drug.

14.SUSPECT DRUG(S) (Continuation...)

Product-Reaction Level

1) Drug	: Eligard® (Leuprolide acetate)
Active Substance	: 1) Leuprolide acetate
Drug Characterization	: Suspect
Form Strength	: 1) 22.5 Milligram
Form of Admin	: 1) Injection
Lot Number	: 1) Unknown
Daily Dose	: (22.5 milligram(s), 1 in 3 Month)
Route of Admin	: 1) Subcutaneous
Indications	: 1) Precocious puberty [10058084 - Precocious puberty]
Therapy Dates	: 1) From : 21/Feb/2024 To :19/May/2025

Continuation Sheet for CIOMS report

Therapy Duration : 1) 454 Days
Action(s) Taken With Drug : Drug withdrawn

Causality

1) Off-label use (Off label use - 10053762, Off label use - 10053762)
Causality as per reporter : Related
Causality as per Mfr : Not Related
DeChallenge : Not applicable
ReChallenge : Not Applicable
2) Cessation of therapy (Therapy cessation - 10065154, Therapy cessation - 10065154)
Causality as per reporter : Not Reported
Causality as per Mfr : Not Related
DeChallenge : Not applicable
ReChallenge : Not Applicable

Labeling :

1) Off-label use
CORE UnLabeled
2) Cessation of therapy
CORE UnLabeled

2) Drug : Eligard® Unspecified Device (Leuprolide acetate)
Active Substance : 1) Leuprolide acetate
Drug Characterization : Suspect
Form of Admin : 1) Injection
Lot Number : 1) Unknown
Route of Admin : 1) Subcutaneous
Indications : 1) Precocious puberty [10058084 - Precocious puberty]
Therapy Dates : 1) From : 21/Feb/2024 To :19/May/2025
Therapy Duration : 1) 454 Days
Action(s) Taken With Drug : Not applicable

Causality

1) Off-label use (Off label use - 10053762, Off label use - 10053762)
Causality as per reporter : Related
Causality as per Mfr : Not Related
DeChallenge : Not applicable
ReChallenge : Not Applicable
2) Cessation of therapy (Therapy cessation - 10065154, Therapy cessation - 10065154)
Causality as per reporter : Not Reported
Causality as per Mfr : Not Related
DeChallenge : Not applicable
ReChallenge : Not Applicable

Labeling :

1) Off-label use
CORE
2) Cessation of therapy
CORE